Epcoritamab Regimen for Follicular Lymphoma Treatment
- The epcoritamab regimen is a promising new treatment for follicular lymphoma, especially because its now showing effectiveness as a second-line therapy (meaning it's used when the first treatment...
- * Second-Line Therapy: A significant advancement, as it allows for a more powerful treatment to be used earlier in the disease course.
- * full Healio Coverage: https://www.healio.com/news/hematology-oncology/20251208/epcoritamab-regimen-sets-new-benchmark-in-advanced-follicular-lymphoma * Healio AI: The article also promotes Healio AI, a tool for accessing clinical information.
Here’s a breakdown of the key details from the provided text:
Main Point:
The epcoritamab regimen is a promising new treatment for follicular lymphoma, especially because its now showing effectiveness as a second-line therapy (meaning it’s used when the first treatment doesn’t work). previously,bispecific antibodies like epcoritamab were only approved for use in later stages of treatment.
Key Details:
* Epcoritamab: A bispecific antibody.
* Follicular Lymphoma: The type of cancer being treated.
* Second-Line Therapy: A significant advancement, as it allows for a more powerful treatment to be used earlier in the disease course.
* Dr. Brian T. Hill (Cleveland Clinic): Expresses excitement about the availability of this treatment option and anticipates further improvements in how it’s used. He can be contacted at hillb2@ccf.org.
* Study Presentation: The research was presented at the ASH (American Society of Hematology) Annual Meeting and Exposition in December 2025.
* Source: Healio Interviews.
* Disclosure: Dr. Hill has financial relationships with several pharmaceutical companies (AbbVie, AstraZeneca, BMS, Genentech, and Genmab Medicines).
Where to find more information:
* full Healio Coverage: https://www.healio.com/news/hematology-oncology/20251208/epcoritamab-regimen-sets-new-benchmark-in-advanced-follicular-lymphoma
* Healio AI: The article also promotes Healio AI, a tool for accessing clinical information.